Compare · PLSE vs WST
PLSE vs WST
Side-by-side comparison of Pulse Biosciences Inc (PLSE) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PLSE and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $22.35B, about 13.1x PLSE ($1.71B).
- Over the past year, PLSE is up 45.8% and WST is up 51.0% - WST leads by 5.2 points.
- PLSE has been more active in the news (9 items in the past 4 weeks vs 6 for WST).
- WST has more recent analyst coverage (15 ratings vs 5 for PLSE).
- Company
- Pulse Biosciences Inc
- West Pharmaceutical Services Inc.
- Price
- $24.63-1.48%
- $315.91-2.11%
- Market cap
- $1.71B
- $22.35B
- 1M return
- +16.12%
- +6.16%
- 1Y return
- +45.78%
- +51.02%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2016
- News (4w)
- 9
- 6
- Recent ratings
- 5
- 15
Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue primarily for dermatology applications by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest PLSE
- Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
- Amendment: Director Duggan Robert W bought $12,999,988 worth of shares (660,233 units at $19.69), increasing direct ownership by 1% to 48,370,047 units (SEC Form 4)
- SEC Form 10-Q filed by Pulse Biosciences Inc
- Amendment: SEC Form SCHEDULE 13D/A filed by Pulse Biosciences Inc
- ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million
- Amendment: Chief Executive Officer Laviolette Paul A bought $295,350 worth of shares (15,000 units at $19.69), increasing direct ownership by 1,773% to 15,846 units (SEC Form 4)
- Chief Executive Officer Laviolette Paul A bought $295,350 worth of shares (15,000 units at $19.69) (SEC Form 4)
- Director Duggan Robert W bought $12,999,988 worth of shares (660,233 units at $19.69), increasing direct ownership by 1% to 48,211,433 units (SEC Form 4)
- SEC Form DEF 14A filed by Pulse Biosciences Inc
- Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
Latest WST
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SVP, Proprietary Segment Campbell Shane Alden covered exercise/tax liability with 219 shares and converted options into 770 shares, increasing direct ownership by 881% to 613 units (SEC Form 4)
- SEC Form SD filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)
- Director Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)
- Director Lockhart Stephen H was granted 791 shares, increasing direct ownership by 29% to 3,523 units (SEC Form 4)
- Director Lai Goldman Myla was granted 791 shares, increasing direct ownership by 4% to 20,435 units (SEC Form 4)